Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8236962 | MYCOVIA PHARMS | Metalloenzyme inhibitor compounds |
Apr, 2031
(7 years from now) | |
US10414751 | MYCOVIA PHARMS | Antifungal compounds and processes for making |
Mar, 2036
(12 years from now) | |
US9840492 | MYCOVIA PHARMS | Antifungal compounds and processes for making |
Mar, 2036
(12 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8754227 | MYCOVIA PHARMS | Metalloenzyme inhibitor compounds |
Apr, 2031
(7 years from now) | |
US11247981 | MYCOVIA PHARMS | Metalloenzyme inhibitor compounds |
May, 2033
(9 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Apr 26, 2027 |
Generating Antibiotic Incentives Now (GAIN) | Apr 26, 2032 |
Drugs and Companies using OTESECONAZOLE ingredient
NCE-1 date: 2031-04-27
Market Authorisation Date: 26 April, 2022
Treatment: Vivjoa is indicated to reduce the incidence of recurrent vulvovaginal candidiasis (rvvc) in females with a history of rvvc who are not of reproductive potential
Dosage: CAPSULE;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic